Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Remains a Buy on Ocular Therapeutix (OCUL)
Baird Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $17
Ocular Therapeutix Price Target Announced at $22.00/Share by Scotiabank
Ocular Therapeutix Analyst Ratings
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $14
BofA Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Buy Rating on Ocular Therapeutix: Accelerated Phase 3 Trial Enrollment and Promising 2025 Outlook
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
Ocular Therapeutix Analyst Ratings
Positive Outlook for Ocular Therapeutix: Buy Rating Affirmed Amidst FDA Alignment and Promising Trial Progress
Buy Rating Justified by Ocular Therapeutix's Rapid SOL-1 Trial Progress and Positive FDA Feedback on SOL-R
Ocular Therapeutix Price Target Maintained With a $14.00/Share by HC Wainwright & Co.
Ocular Therapeutix Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $14 Price Target
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $14
JMP Securities Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $22
Optimistic Buy Rating for Ocular Therapeutix Amid Promising Axpaxli Trials and Strategic Execution